More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.24B
EPS
0.48
P/E ratio
37.2
Price to sales
2
Dividend yield
--
Beta
1.268391
Previous close
$17.90
Today's open
$17.99
Day's range
$17.77 - $18.12
52 week range
$9.20 - $19.26
show more
CEO
Chirag Patel
Employees
8300
Headquarters
Bridgewater, NJ
Exchange
Nasdaq Global Select
Shares outstanding
348296017
Issue type
Common Stock
Healthcare
Pharmaceuticals
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Zacks Investment Research • Aug 20, 2026

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.
Business Wire • Aug 19, 2026

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Zacks Investment Research • Aug 18, 2026

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Zacks Investment Research • Aug 12, 2026

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Zacks Investment Research • Aug 12, 2026

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Zacks Investment Research • Aug 12, 2026

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Investment Research • Aug 11, 2026

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.
GlobeNewsWire • Aug 10, 2026

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Aug 7, 2026

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Zacks Investment Research • Jul 31, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amneal Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.